Systemic model of chronic benzodiazepine use among mature adults

Aging & Mental Health
Guilhème PérodeauKieron O'Connor

Abstract

Our goal was to build a systemic model of chronic use among community-dwelling mature benzodiazepine (BZD) users. BZDs are commonly prescribed for symptoms of anxiety and/or insomnia despite their documented side effects over time. We conducted in-depth interviews with 23 mature (50 years and over) users, 14 women and 9 men, as well as 9 general practitioners and 11 pharmacists. We chose the grounded theory approach for our analysis. Results yielded a systemic model of chronic BZD use, illustrating onset and maintenance of use, and taking into account individual life context, intervening conditions (e.g. family and doctor--patient interactions) and structural factors (medicalization, ageism, influence of the media and pharmaceutical industry, etc.). Based on our findings, we suggest that intervention should go beyond medical issues and extend to the individual's perception of aging in the modern society, as well as attitudes of families and health professionals regarding long-term BZD use. Family members should be involved in the weaning process and adoption of new life habits. General practitioners should be better trained regarding geriatric psychosocial issues and offer alternatives to prescribe psychotropic drugs such as co...Continue Reading

References

Apr 25, 2000·Australian and New Zealand Journal of Public Health·A F JormG A Broe
Jul 14, 2000·Journal of the American Geriatrics Society·M EganJ Monette
Feb 5, 2002·CNS Drugs·Jane R Mort, Rajender R Aparasu
Oct 5, 2002·The Journal of Clinical Psychiatry·Maurice M Ohayon, Malcolm H Lader
Sep 1, 2004·Expert Opinion on Drug Safety·Subramoniam Madhusoodanan, Olivera J Bogunovic
Sep 27, 2006·Archives of Internal Medicine·Derjung M TarnNeil S Wenger
Mar 16, 2007·Journal of General Internal Medicine·Joan M CookJames C Coyne
Apr 25, 2007·Journal of General Internal Medicine·Chaim M BellPaula A Rochon
Dec 21, 2007·British Journal of Clinical Pharmacology·Hendrika J LuijendijkBruno H Ch Stricker
Feb 7, 2009·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Joseph T HanlonStephanie A Studenski
Jan 25, 2011·Social Psychiatry and Psychiatric Epidemiology·Caroline M SonnenbergAartjan T F Beekman
Mar 5, 2011·Sociology of Health & Illness·Simon J WilliamsJonathan Gabe
Oct 22, 2011·Journal of Women & Aging·Guilhème PérodeauEmilie Grenon
Dec 3, 2011·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Lisa Nissen
Mar 2, 2012·Journal of the American Geriatrics Society·UNKNOWN American Geriatrics Society 2012 Beers Criteria Update Expert Panel
Jul 18, 2012·Canadian Journal on Aging = La Revue Canadienne Du Vieillissement·Michel PrévilleYola Moride
Jul 28, 2012·Research in Social & Administrative Pharmacy : RSAP·Barbara FarrellSamantha Evans
Sep 25, 2012·Santé mentale au Québec·Annick RouleauCynthia Gagnon

❮ Previous
Next ❯

Citations

Jul 11, 2019·Cadernos de saúde pública·Claudia FegadolliElisaldo Luis de Araújo Carlini
May 6, 2021·The British Journal of General Practice : the Journal of the Royal College of General Practitioners·Erin OldenhofPetra K Staiger

❮ Previous
Next ❯

Software Mentioned

SPSS
NVivo

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here